

November 20, 2009

To those concerned

R-Tech Ueno, Ltd.  
(Code No.4573, Osaka Securities Exchange; Hercules)  
Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo  
Representative: Yukihiro Mashima,  
Representative Director & President  
Contact: Koji Nakamura, Business Management Department;  
TEL: 03-(3596) 8011

### Amitiza® Capsules Approved for Sale in Switzerland

Sucampo Pharmaceuticals, Inc. (SPI) announced in a press release dated November 19, 2009 that its wholly owned subsidiary Sucampo Pharma Europe, Ltd. (SPE), which operates in Europe, has received regulatory approval to sell in Switzerland Amitiza® capsules, a treatment for chronic idiopathic constipation.

R-Tech Ueno, Ltd. has an agreement with SPE that grants exclusive rights to manufacture and sell Amitiza® capsules. Currently, R-Tech Ueno sells this drug to Takeda Pharmaceutical Company Limited for distribution in North America. With the drug now approved for sale in Switzerland as well, R-Tech Ueno plans to start producing Amitiza® capsules for sale to SPE, which will distribute the drug in Switzerland.

Approval of Amitiza® capsules in Switzerland will have no effect on results of operations in the fiscal year ending in March 2010.